Alcanza Clinical Research has announced its acquisition of Accel Research Sites Network for an undisclosed price.
Accel Research Sites Network is a multi-specialty network headquartered in Florida, with additional sites in Alabama and Georgia. Accel’s network of 22 sites includes eight clinical research units and 14 embedded sites strategically placed in healthcare settings across the Southeast United States.
Alcanza Clinical Research is a network of research facilities focused on bringing clinical trial opportunities involving life-changing treatments and vaccines to all patients, especially those from underrepresented communities. With locations in Alabama, Florida, Georgia, Massachusetts, Michigan, New Hampshire, South Carolina and Virginia, it specializes in a range of conditions across psychiatry, neurology, dermatology and infectious disease therapeutic areas.
Accel’s site operations will be integrated into Alcanza’s centralized platform while retaining its name and brand identity.
According to data captured in the LevinPro HC database, this transaction represents the 18th clinical trials acquisition of 2023. This also marks Alcanza’s first transaction of 2023. In 2022, the company acquired Charlottesville Medical Research, a research facility based in Charlottesville, Virginia specializing in Phase II-IV studies across a host of therapeutic areas.
